Merck KGaA reports Phase I response data for M7824 in NSCLC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE